What did the US FDA find during the Granules Consumer Health inspection?

The US FDA found zero observations during the recent GMP inspection of Granules Consumer Health.

Is Granules Consumer Health a new facility inspected by the FDA?

No, this was the second FDA inspection for Granules Consumer Health, following an audit in March 2023.

What role does Granules Consumer Health play for Granules India?

Granules Consumer Health is Granules India's packaging and distribution site for OTC products in the US.

Home / Business and Economy / Granules India Facility Aces US FDA Inspection

Granules India Facility Aces US FDA Inspection

4 Dec

•

Summary

Granules Consumer Health passed a US FDA GMP inspection.
The facility had zero observations from the US regulatory body.
This marks the second successful FDA inspection for the site.

Granules India Facility Aces US FDA Inspection

Granules India's US-based subsidiary, Granules Consumer Health, has achieved a significant milestone by successfully completing a Good Manufacturing Practices (GMP) inspection conducted by the US Food and Drug Administration (FDA). The inspection resulted in zero observations, highlighting the facility's stringent adherence to regulatory standards.

This inspection marks the second successful audit for Granules Consumer Health, following a previous audit in March 2023 that yielded a No Action Indicated (NAI) classification. The company emphasized its unwavering commitment to quality, safety, and regulatory excellence.

Granules Consumer Health serves as the company's primary front-end division for over-the-counter products in the United States. It effectively leverages Granules India's established manufacturing efficiencies, robust regulatory compliance, and integrated supply chain capabilities to serve the US market.